Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells os Bone Marrow on Functional Recovery in Patients With Dilated Cardiomyopathy and Heart Failure.

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2014 by Fundación Pública Andaluza Progreso y Salud
Sponsor:
Collaborator:
Iniciativa Andaluza en Terapias Avanzadas
Information provided by (Responsible Party):
Fundación Pública Andaluza Progreso y Salud
ClinicalTrials.gov Identifier:
NCT02033278
First received: January 9, 2014
Last updated: NA
Last verified: January 2014
History: No changes posted

January 9, 2014
January 9, 2014
January 2014
January 2017   (final data collection date for primary outcome measure)
Changes in ventricular function determined angiographically [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Degree of clinical improvement based on the absence of major cardiac events (MACE) during follow-up [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Presence or absence of symptoms or arrhythmias [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Evolution time since diagnosis of idiopathic dilated cardiomyopathy to the inclusion of the patient. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells os Bone Marrow on Functional Recovery in Patients With Dilated Cardiomyopathy and Heart Failure.
Multicenter Phase III Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Dilated Cardiomyopathy and Heart Failure.

Clinical trial phase III, double-blind, randomized, controlled with placebo. There is sufficient preliminary evidence to consider intracoronary injection of bone marrow progenitor cells as a viable, safe and beneficial treatment in patients with dilated cardiomyopathy, although the biological mechanism of action of bone marrow cells in the myocardium is not known. In this project we propose to investigate comparatively and from a biological and clinical point of view the applicability of regenerative therapy with autologous bone marrow cells in patients with dilated cardiomyopathy.

The study population correspond to male and female patients with idiopathic dilated cardiomyopathy.

51 patients diagnosed with this disease are included. After inclusion, will proceed to the random allocation to study group or control group in a 2:1 ratio, 34 patients in the treatment group and 17 in the control group.

The total duration is expected to be 36 months: The inclusion period is 24 months and each patient will be followed for 12 months. Upon completion thereof, the patients will be followed in routine clinical practice.

This is a double blind study, in which all patients were will perform the bone marrow harvesting.

All patients will receive the best medical treatment individualized (ACEIs or Angiotensin II receptor blocker, beta-blockers, diuretics and eplerenone) for at least 6 months prior to their participation in the clinical trial, so that the situation is stable and pharmacological basal condition is the same for everyone.

The bone marrow cells of patients assigned to placebo group will be cryopreserved, and once the trial is completed, the blind will be opened and all the patients who had been randomized to the control group, may be processed by the route of compassionate use with their own mononuclear bone marrow cells previously frozen.

Randomization of patients, will be centralized by the sponsor or contract research organization designated for such purpose. In both treatment groups will be stratified by a condition (age> or ≤ 45 years). The final probability of treatment assignment will be conditioned by the number of patients included in each group (2:1) and the number of patients who meet the inclusion each condition.

The main objective is to assess comparative the efficacy of intracoronary injection of bone marrow stem cells autologous to improve ventricular function in patients with idiopathic dilated cardiomyopathy who receive conventional medical treatment, compared with a control group who receive a infusion of placebo and conventional medical treatment. The improvement in ventricular function assessed by changes in angiographically determined ejection fraction.

Secondary objectives of the study are:

- To analyze the predictors of good clinical response, functional and biological treatment with adult stem cells autologous mononuclear bone marrow not expanded in terms of functional recovery.

The following parameters were evaluated: Functional class (NYHA), natriuretic peptide B, stress test (exercise time) and echocardiographic parameters of ventricular function.

- To determine, in the light of the obtained results, the application protocol suitable cell therapy for the treatment of dilated cardiomyopathy

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Idiopathic Dilated Cardiomyopathy
  • Drug: Infusion of autologous mononuclear bone marrow cells
    Infusion of autologous mononuclear bone marrow cells more conventional medical treatment
  • Drug: Placebo infusion
    Placebo infusion more conventional medical treatment
  • Experimental: Infusion of autologous mononuclear bone marrow cells
    Infusion of autologous mononuclear bone marrow cells more conventional medical treatment
    Intervention: Drug: Infusion of autologous mononuclear bone marrow cells
  • Placebo Comparator: Placebo infusion
    Placebo infusion more conventional medical treatment
    Intervention: Drug: Placebo infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
51
January 2017
January 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients of both sexes and ages between 18 and 70 years.
  2. Patients diagnosed with dilated cardiomyopathy established by echocardiography with symptoms and / or signs of heart failure of idiopathic etiology.
  3. Minimum evolution since diagnosis 6 months
  4. Absence of coronary lesions tested with multislice CT and / or hemodynamic study
  5. Patients with stable medical therapy for at least 6 months prior to enrollment (either individually adjusted according to B-type natriuretic peptide and functional status).
  6. Ejection fraction of the left ventricle <40% or ejection fraction of the left ventricle 40% -50% if left ventricular tele-diastolic volume> 110 ml/m2.
  7. Presence of sinus rhythm.
  8. Patients give their informed consent for participation in the clinical trial consent.
  9. Normal laboratory parameters, defined by:

    • Leukocytes ≥ 3000
    • Neutrophils ≥ 1500
    • Platelets ≥ 100,000
    • Aspartate aminotransferase / Alanine aminotransferase ≤ 2.5 standard range institution
    • Creatinine ≤ 2.5 mg / dl
  10. Women of childbearing potential must have negative results on a pregnancy test at the time of inclusion in the study and agree to use a medically approved method of contraception while on study.

Exclusion Criteria:

  1. Dilated cardiomyopathy of toxic origin, or ischemic storage diseases.
  2. Recent history of myocarditis.
  3. Patients amenable to treatment with resynchronization
  4. Patients in active waiting list for heart transplantation.
  5. Coexistence of other serious systemic diseases.
  6. Coexistence of any type of blood disease
  7. Pregnant women, lactating, or of childbearing age not using effective contraception.
  8. Patients who are currently participating or have completed their participation in a clinical trial at a period less than 3 months.
  9. Patients with malignant or pre-malignant tumors
  10. Positive serology for hepatitis B virus, hepatitis C virus or human immunodeficiency virus.
  11. Patients at the time of study entry are taking any medications prohibited by the protocol.
Both
18 Years to 70 Years
No
Contact: Ana Cardesa 0034 955014090 ana.cardesa@juntadeanlacia.es
Spain
 
NCT02033278
CMMo/MD/2013
Yes
Fundación Pública Andaluza Progreso y Salud
Fundación Pública Andaluza Progreso y Salud
Iniciativa Andaluza en Terapias Avanzadas
Principal Investigator: José Suárez de Lezo Cruz Conde, MD, PhD Hospital Universitario Reina Sofía
Principal Investigator: Eduardo de Teresa Galván, MD, PhD Hospital Universitario Virgen de la Victoria
Principal Investigator: Luis Pastor Torre, MD, PhD Hospital Universitario de Valme
Principal Investigator: Manuel Sancho Jaldón, MD, PhD Hospital Universitario Puerta del Mar
Fundación Pública Andaluza Progreso y Salud
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP